Respiratory syncytial virus is associated with significant neonatal and infant morbidity and mortality. Maternal bivalent respiratory syncytial virus prefusion F respiratory syncytial virus vaccination to protect neonates and infants was approved in September 2023 for administration between 32+0 and 36+6 weeks to protect neonates and infants. This approved timeframe is narrower than the 24 to 36 week window evaluated in the clinical trial, due to the possible association between preterm birth and vaccine administration. Currently, data are lacking on how maternal vaccine timing within the approved window affects the transfer of antibodies from mother to fetus, critical information that could influence clinical practice.

中文翻译：

---

提高胎盘抗体转移效率，延长母体呼吸道合胞病毒疫苗接种与出生之间的间隔


呼吸道合胞病毒与显著的新生儿和婴儿发病率和死亡率相关。2023 年 9 月，母体二价呼吸道合胞病毒融合前流感 F 呼吸道合胞病毒疫苗接种被批准用于保护新生儿和婴儿，用于保护新生儿和婴儿。由于早产与疫苗接种之间可能存在关联，因此该批准的时间范围比临床试验中评估的 24 至 36 周窗口窄。目前，缺乏关于在批准窗口内母体接种疫苗的时间如何影响抗体从母亲到胎儿的转移的数据，这些信息可能会影响临床实践。